Resources Jobs
Jobs
Postings are free of charge for announcements or services provided by nonprofit institutions. There may be fee for postings by for-profit entities. Posting is at the discretion of the Society for Glycobiology. Email us with full text to post.
Posted: June 27, 2019
Research Scientist Position in Glycoproteomics Influenza Systems Biology Lab
Location:
A research scientist position in glycoproteomics is available at the Influenza Systems Biology Laboratory, which is affiliated across Department of Molecular Microbiology and Immunology, School of Medicine, Department of Electrical Engineering and Computer Science, College of Engineering , Department of Veterinary Pathobiology, College of Veterinary Medicine, and
Informatics Institute at University of Missouri (MU). The lab is physically located at MU Bond Life Science Center. The mission of this lab is to study ecology, evolution, and host-pathogen interactions for emerging and re-emerging infectious diseases, especially influenza viruses by developing and applying integrated, multi-scale, and evidence-based approaches that combining laboratory, clinical and computational methods Excellent oral and written communication skills, the ability to work independently and in a team and a broad interest in Systems Biology are expected.
 
Posted: April 8, 2019
Research Scientists at GlycoBac
Location:
Dr. Donald Jarvis is seeking two motivated individuals to serve as Research Scientists at GlycoBac, LLC  (http://www.glycobac.com/), a small biotechnology company created in 2011. GlycoBac’s primary mission is to refine and commercialize improved baculovirus-insect cell platforms for recombinant protein and biologics production. One major effort focuses on glycoengineered baculovirus vectors and insect cell lines originally developed in Dr. Jarvis’ academic labs at Texas A&M University and the University of Wyoming (https://www.uwyo.edu/molecbio/faculty-and-staff/don-jarvis/). Refinement of these tools will yield new expression systems that can be used to manufacture recombinant glycoproteins with specific, pre-selected glycosylation profiles, including humanized profiles, that enhance their properties. Another major effort focuses on a current product already developed by GlycoBac, which is a virus-free insect cell line (Spodoptera frugiperda rhabdovirus negative; Sf-RVN). In a key partnership with MilliporeSigma, we are licensing Sf-RVN cells for use in biologics manufacturing. In addition, we are using Sf-RVN cells for Sf-rhabdovirus infectivity assays designed to detect contamination in insect cell lines use for and materials produced in insect cell-based manufacturing processes.